Terms: = Breast cancer AND DNMT3A, Q9Y6K1, 1788, ENSG00000119772, DNMT3A2, M_HsaIIIA AND Prognosis
18 results:
1. The chromatin architectural regulator SND1 mediates metastasis in triple-negative breast cancer by promoting CDH1 gene methylation.
Zhang H; Gao M; Zhao W; Yu L
Breast Cancer Res; 2023 Oct; 25(1):129. PubMed ID: 37885030
[TBL] [Abstract] [Full Text] [Related]
2. In Silico Identification of a BRCA1:miR-29:DNMT3 Axis Involved in the Control of Hormone Receptors in BRCA1-Associated breast cancers.
Santarosa M; Baldazzi D; Armellin M; Maestro R
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373065
[TBL] [Abstract] [Full Text] [Related]
3. dnmt3a-dermatopontin axis suppresses breast cancer malignancy via inactivating YAP.
Ye D; Wang Y; Deng X; Zhou X; Liu D; Zhou B; Zheng W; Wang X; Fang L
Cell Death Dis; 2023 Feb; 14(2):106. PubMed ID: 36774339
[TBL] [Abstract] [Full Text] [Related]
4. MGL S3 Chimeric Enzyme Drives Apoptotic Death of EGFR-Dependent cancer Cells through ERK Downregulation.
Bondarev N; Ivanenko K; Khabusheva E; Lebedev T; Manukhov I; Prassolov V
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361596
[TBL] [Abstract] [Full Text] [Related]
5. CircPTPRM accelerates malignancy of papillary thyroid cancer via miR-885-5p/dnmt3a axis.
Chen D; Jiang X; Luo H; Hua Q; Zhang F
J Clin Lab Anal; 2022 Oct; 36(10):e24688. PubMed ID: 36098040
[TBL] [Abstract] [Full Text] [Related]
6. Aberrant promoter hypermethylation inhibits RGMA expression and contributes to tumor progression in breast cancer.
Li Y; Liu HT; Chen X; Wang YW; Tian YR; Ma RR; Song L; Zou YX; Gao P
Oncogene; 2022 Jan; 41(3):361-371. PubMed ID: 34754080
[TBL] [Abstract] [Full Text] [Related]
7. Silence of lncRNA MIAT-mediated inhibition of DLG3 promoter methylation suppresses breast cancer progression via the Hippo signaling pathway.
Li D; Hu X; Yu S; Deng S; Yan M; Sun F; Song J; Tang L
Cell Signal; 2020 Sep; 73():109697. PubMed ID: 32593652
[TBL] [Abstract] [Full Text] [Related]
8. Methylation-mediated silencing of miR-133a-3p promotes breast cancer cell migration and stemness via miR-133a-3p/MAML1/dnmt3a positive feedback loop.
Shi W; Tang T; Li X; Deng S; Li R; Wang Y; Wang Y; Xia T; Zhang Y; Zen K; Jin L; Pan Y
J Exp Clin Cancer Res; 2019 Oct; 38(1):429. PubMed ID: 31660998
[TBL] [Abstract] [Full Text] [Related]
9. dnmt3a/3B overexpression might be correlated with poor patient survival, hypermethylation and low expression of ESR1/PGR in endometrioid carcinoma: an analysis of The cancer Genome Atlas.
He D; Wang X; Zhang Y; Zhao J; Han R; Dong Y
Chin Med J (Engl); 2019 Jan; 132(2):161-170. PubMed ID: 30614867
[TBL] [Abstract] [Full Text] [Related]
10. MYC and dnmt3a-mediated DNA methylation represses microRNA-200b in triple negative breast cancer.
Pang Y; Liu J; Li X; Xiao G; Wang H; Yang G; Li Y; Tang SC; Qin S; Du N; Zhang H; Liu D; Sun X; Ren H
J Cell Mol Med; 2018 Dec; 22(12):6262-6274. PubMed ID: 30324719
[TBL] [Abstract] [Full Text] [Related]
11. DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine.
Yu J; Qin B; Moyer AM; Nowsheen S; Liu T; Qin S; Zhuang Y; Liu D; Lu SW; Kalari KR; Visscher DW; Copland JA; McLaughlin SA; Moreno-Aspitia A; Northfelt DW; Gray RJ; Lou Z; Suman VJ; Weinshilboum R; Boughey JC; Goetz MP; Wang L
J Clin Invest; 2018 Jun; 128(6):2376-2388. PubMed ID: 29708513
[TBL] [Abstract] [Full Text] [Related]
12. TNM classification and the need for revision of pN3a breast cancer.
van Nijnatten TJA; Moossdorff M; de Munck L; Goorts B; Vane MLG; Keymeulen KBMI; Beets-Tan RGH; Lobbes MBI; Smidt ML
Eur J Cancer; 2017 Jul; 79():23-30. PubMed ID: 28458119
[TBL] [Abstract] [Full Text] [Related]
13. MiR-101 reverses the hypomethylation of the LMO3 promoter in glioma cells.
Liu X; Lei Q; Yu Z; Xu G; Tang H; Wang W; Wang Z; Li G; Wu M
Oncotarget; 2015 Apr; 6(10):7930-43. PubMed ID: 25829251
[TBL] [Abstract] [Full Text] [Related]
14. DNA methyltransferase 1/3a overexpression in sporadic breast cancer is associated with reduced expression of estrogen receptor-alpha/breast cancer susceptibility gene 1 and poor prognosis.
Yu Z; Xiao Q; Zhao L; Ren J; Bai X; Sun M; Wu H; Liu X; Song Z; Yan Y; Mi X; Wang E; Jin F; Wei M
Mol Carcinog; 2015 Sep; 54(9):707-19. PubMed ID: 24464625
[TBL] [Abstract] [Full Text] [Related]
15. miR-200b and miR-200c as prognostic factors and mediators of gastric cancer cell progression.
Tang H; Deng M; Tang Y; Xie X; Guo J; Kong Y; Ye F; Su Q; Xie X
Clin Cancer Res; 2013 Oct; 19(20):5602-12. PubMed ID: 23995857
[TBL] [Abstract] [Full Text] [Related]
16. DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines.
Roll JD; Rivenbark AG; Jones WD; Coleman WB
Mol Cancer; 2008 Jan; 7():15. PubMed ID: 18221536
[TBL] [Abstract] [Full Text] [Related]
17. Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas.
Girault I; Tozlu S; Lidereau R; Bièche I
Clin Cancer Res; 2003 Oct; 9(12):4415-22. PubMed ID: 14555514
[TBL] [Abstract] [Full Text] [Related]
18. Intravenous, intralesional and endolymphatic administration of lymphokines in human cancer.
Pulley MS; Nagendran V; Edwards JM; Dumonde DC
Lymphokine Res; 1986; 5 Suppl 1():S157-63. PubMed ID: 3784610
[TBL] [Abstract] [Full Text] [Related]
